Drug development remains a critical focus within the global pharmaceutical industry. To
date, more than 80% of disease targets are considered difficult to target. The emergence of …

Targeted protein degradation refers to the use of small molecules to induce the selective
degradation of proteins. In its most common form, this degradation is achieved through …

Tuberculosis (TB) drug discovery and development has undergone nothing short of a
revolution over the past 20 years. Successful public–private partnerships and sustained …

Antimicrobial resistance is a global health threat that requires the development of new
treatment concepts. These should not only overcome existing resistance but be designed to …

Antibiotics form our frontline therapy against disease-causing bacteria. Unfortunately,
antibiotic resistance is becoming more common, threatening a future where these …

Caseinolytic protease P (ClpP) responsible for the proteolysis of damaged or misfolded
proteins plays a critical role in proteome homeostasis. MtbClpP1P2, a ClpP enzyme …

Tuberculosis (TB), an airborne infectious disease caused by Mycobacterium tuberculosis,
has become the leading cause of death. The subsequent emergence of multidrug-resistant …

Proteolysis-targeting chimeras (PROTACs) represent a new therapeutic modality involving
selectively directing disease-causing proteins for degradation through proteolytic systems …

Proteolysis-targeting chimeras (PROTACs) describe compounds that bind to and induce
degradation of a target by simultaneously binding to a ubiquitin ligase. More generally …

Targeted protein degradation (TPD) has greatly advanced as a therapeutic strategy in the
past two decades, and we are on the cusp of rationally designed protein degraders reaching …